Menopause in rheumatology: what is important for gynecologist to know?

Panevin T.S., Smetnik A.A.

1) V.A. Nasonova Research Institute of Rheumatology, Ministry of Science and Education of the Russian Federation, Moscow, Russia; 2) Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russia
Most rheumatic diseases are characterized by sexual dimorphism, while the greatest numbers of patients are women at the rheumatologist’s office. Moreover, rheumatic and other diseases are typified by a certain age of their onset, and a number of rheumatic diseases develop in peri- and postmenopause. On the other hand, it is known that the course of many rheumatic diseases can be variable with a woman’s reproductive status change: the onset of pregnancy or menopause. Finally, the traditional therapy (menopausal hormone therapy (MHT)) used to relieve menopausal symptoms may not be prescribed in rheumatic diseases in some cases for no reasonable reason. This publication considers the most pressing issues of menopause and menopausal syndrome, according to the authors’ opinion, in patients with various rheumatic diseases, which can be useful for a gynecologist in everyday practice.
Conclusion: Extensive experience in using MHT for various rheumatic diseases has been currently accumulated. Undoubtedly, MHT should not be considered as a component of the treatment of rheumatic diseases; however, a rheumatic disease must not deem as an absolute contraindication to MHT either. The final decision on the prescription of MHT in difficult situations should be made collectively with the participation of a rheumatologist, a gynecologist, and a patient who is well aware of benefits and risks.

Authors' contributions: Panevin T.S. – concept, search work, writing the text; Smetnik A.A. – writing, editing the text; final approval of the manuscript.
Conflicts of interest: The authors declare that there are no possible conflicts of interest.
Funding: Search and analytical work was done without financial support.
For citation: Panevin T.S., Smetnik A.A.
Menopause in rheumatology: what is important for gynecologist to know?
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2023; (8): 30-37 (in Russian)


menopausal hormone therapy
rheumatoid arthritis
systemic connective tissue diseases


  1. Barnabei V.M., Cochrane B.B., Aragaki A.K., Nygaard I., Williams R.S., McGovern P.G. et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet. Gynecol. 2005; 105(5, Pt. 1): 1063-73.
  2. Ho S.C., Chan S.G., Yip Y.B., Cheng A., Yi Q., Chan C. et al. Menopausal symptoms and symptom clustering in Chinese women. Maturitas. 1999; 33(3): 219-27.
  3. Horimoto Y., Saito M., Kasumi F. Arthralgia in 329 patients taking aromatase inhibitors. Breast Care (Basel). 2009; 4(5): 319-23.
  4. Sestak I., Cuzick J., Sapunar F., Eastell R., Forbes J.F., Bianco A.R., Buzdar A.U.; ATAC Trialists' Group. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 2008; 9(9): 866-72.
  5. Паневин Т.С., Бобкова А.О., Каратеев А.Е., Зоткин Е.Г. Дефицит эндогенных эстрогенов и развитие хронической скелетно-мышечной боли. Терапевтический архив. 2022; 94(5): 683-8. [Panevin T.S., Bobkova A.O., Karateev A.E., Zotkin E.G. Endogenous estrogen deficiency and the development of chronic musculoskeletal pain: a review. Terapevticheskii Arkhiv. 2022; 94(5): 683-8. (in Russian)].
  6. Nilsson B.O. Modulation of the inflammatory response by estrogens with focus on the endothelium and its interactions with leukocytes. Inflamm. Res. 2007; 56(7): 269-73.
  7. Pamuk O.N., Dönmez S., Cakir N. Increased frequencies of hysterectomy and early menopause in fibromyalgia patients: a comparative study. Clin. Rheumatol. 2009; 28(5): 561-4.
  8. Multanen J., Heinonen A., Häkkinen A., Kautiainen H., Kujala U.M., Lammentausta E. et al. Bone and cartilage characteristics in postmenopausal women with mild knee radiographic osteoarthritis and those without radiographic osteoarthritis. J. Musculoskelet. Neuronal Interact. 2015;15(1): 69-77.
  9. Ding C., Cicuttini F., Blizzard L., Scott F, Jones G. A longitudinal study of the effect of sex and age on rate of change in knee cartilage volume in adults. Rheumatology (Oxford). 2007; 46(2): 273-9.
  10. Riancho J.A., García-Ibarbia C., Gravani A., Raine E.V., Rodríguez-Fontenla C., Soto-Hermida A. et al. Common variations in estrogen-related genes are associated with severe large-joint osteoarthritis: a multicenter genetic and functional study. Osteoarthritis Cartilage. 2010; 18(7): 927-33.
  11. Ushiyama T., Ueyama H., Inoue K., Nishioka J., Ohkubo I., Hukuda S. Estrogen receptor gene polymorphism and generalized osteoarthritis. J. Rheumatol. 1998; 25(1): 134-7.
  12. Паневин Т.С., Юренева С.В., Зоткин Е.Г. Менопаузальная гормонотерапия при ревматических заболеваниях: остеоартрит. Акушерство и гинекология. 2021; 12: 50-7. [Panevin T.S., Yureneva S.V., Zotkin E.G. Menopausal hormone therapy for rheumatic diseases: osteoarthritis. Obstetrics and Gynecology. 2021; (12): 50-7. (in Russian)].
  13. Spector T.D., Hart D.J., Brown P., Almeyda J., Dacre J.E., Doyle D.V., Silman A.J. Frequency of osteoarthritis in hysterectomized women. J. Rheumatol. 1991; 18(12): 1877-83.
  14. Hussain S.M., Cicuttini F.M., Alyousef B., Wang Y. Female hormonal factors and osteoarthritis of the knee, hip and hand: a narrative review. Climacteric. 2018; 21(2): 132-9.
  15. Baber R.J., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50.
  16. Паневин Т.С., Юренева С.В. Менопаузальная гормонотерапия при ревматических заболеваниях (подагра). Акушерство и гинекология. 2021; 9: 36-41. [Panevin T.S., Yureneva S.V. Menopausal hormone therapy for rheumatic diseases (gout). Obstetrics and Gynecology. 2021; (9): 36-41.(in Russian)].
  17. Елисеев М.С., Чикаленкова Н.А., Барскова В.Г. Клинические особенности подагры у женщин: результаты сравнительного исследования. Научно-практическая ревматология. 2014; 52(2): 178-82. [Eliseev M.S., Chikalenkova N.A., Barskova V.G. Clinical features of gout in women: the results of a comparative study. Rheumatology Science and Practice. 2014; 52(2): 178-82. (in Russian)].
  18. Hak A.E., Choi H.K. Menopause, postmenopausal hormone use and serum uric acid levels in US women--the Third National Health and Nutrition Examination Survey. Arthritis Res. Ther. 2008; 10(5): R116.
  19. Hak A.E., Curhan G.C., Grodstein F., Choi H.K. Menopause, postmenopausal hormone use and risk of incident gout. Ann. Rheum. Dis. 2010; 69(7): 1305-9.
  20. Bruderer S.G., Bodmer M., Jick S.S., Meier C.R. Association of hormone therapy and incident gout: population-based case-control study. Menopause. 2015; 22(12): 1335-42.
  21. Safiri S., Kolahi A.A., Hoy D., Smith E., Bettampadi D., Mansournia M.A. et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann. Rheum. Dis. 2019; 78(11): 1463-71.
  22. Паневин Т.С., Юренева С.В., Зоткин Е.Г., Кошелева Н.М. Менопаузальная гормонотерапия при ревматоидном артрите. Проблемы репродукции. 2022; 28(1): 149-58. [Panevin T.S., Yureneva S.V., Zotkin E.G., Kosheleva N.M. Morphological structure of the placenta as a result of its increment. Russian Journal of Human Reproduction. 2022; 28(1): 149-58. (in Russian)].
  23. Гордеев А.В., Матьянова Е.В., Олюнин Ю.А., Галушко Е.А., Зоткин Е.Г. Труднолечимый ревматоидный артрит (difficult-to-treat RA) в клинической практике ревматологического стационара. Первый взгляд. Современная ревматология. 2022; 16(2): 13-20. [Gordeev A.V., Matyanova E.V., Olyunin Yu.A. et al. Difficult-to-treat rheumatoid arthritis in the clinical practice of a rheumatological hospital. First look. Modern Rheumatology Journal. 2022; 16(2): 13-20. (in Russian)].
  24. de Hair M.J.H., Jacobs J.W.G., Schoneveld J.L.M., van Laar J.M. Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford). 2018; 57(7): 1135-44.
  25. Henes M., Froeschlin J., Taran F.A., Brucker S., Rall K.K., Xenitidis T. et al. Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behçet's disease and spondyloarthritis on anti-Müllerian hormone levels. Rheumatology (Oxford). 2015; 54(9): 1709-12.
  26. Brouwer J., Dolhain R.J.E.M., Hazes J.M.W., Visser J.A., Laven J.S.E. Reduced ovarian function in female rheumatoid arthritis patients trying to conceive. ACR Open Rheumatol. 2019; 1(5): 327-35.
  27. Walitt B., Pettinger M., Weinstein A., Katz J., Torner J., Wasko M.C. et al. Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials. Arthritis Rheum. 2008; 59(3): 302-10.
  28. Jeong H.S., Hong S.J., Choi S.J., Kim J.H., Song G.G., Jung J.H. Effects of oral contraceptives on rheumatoid arthritis in Korean menopausal women: A nationwide cross-sectional study. Maturitas. 2018; 112: 24-8.
  29. Orellana C., Saevarsdottir S., Klareskog L., Kim J.H., Song G.G., Jung J.H. Postmenopausal hormone therapy and the risk of rheumatoid arthritis: results from the Swedish EIRA population-based case-control study. Eur. J. Epidemiol. 2015; 30(5): 449-57.
  30. Forsblad-d'Elia H., Carlsten H. Hormone replacement therapy in postmenopausal women with rheumatoid arthritis stabilises bone mineral density by digital x-ray radiogrammetry in a randomised controlled trial. Ann. Rheum. Dis. 2011; 70(6): 1167-8.
  31. Daraghmeh D.N., Hopkins A.M., King C., Abuhelwa A.Y., Wechalekar M.D., Proudman S.M. et al. Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs. Rheumatology (Oxford). 2023; 62(2): 583-95.
  32. Паневин Т.С., Попкова Т.В., Решетняк Т.М., Кошелева Н.М., Ледина А.В. Менопаузальная гормонотерапия при системной красной волчанке: pro et contra. Научно-практическая ревматология. 2023; 61(1): 70-6. [Panevin T.S., Popkova T.V., Reshetnyak T.M., Kosheleva N.M., Ledina A.V. Menopausal hormone therapy in systemic lupus erythematosus: Pro et contra. Rheumatology Science and Practice. 2023; 61(1): 70-6. (in Russian)].
  33. Johansson M., Arlestig L., Möller B., Smedby T., Rantapää-Dahlqvist S. Oestrogen receptor {alpha} gene polymorphisms in systemic lupus erythematosus. Ann. Rheum. Dis. 2005; 64(11): 1611-7.
  34. Stavrou I., Zois C., Ioannidis J.P., Tsatsoulis A. Association of polymorphisms of the oestrogen receptor alpha gene with the age of menarche. Hum. Reprod. 2002; 17(4): 1101-5.
  35. Buyon J.P., Wallace D.L. The endocrine system, use of exogenous estrogens, and the urogenital tract. In: Wallace D.J., Hahn B.J., eds. Dubois’ lupus erythematosus. 5th ed. Baltimore: William et Wilkins; 1997: 817-34.
  36. Sammaritano L.R., Bermas B.L., Chakravarty E.E., Chambers C., Clowse M.E.B., Lockshin M.D. et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020; 72(4): 529-56.
  37. Andreoli L., Bertsias G.K., Agmon-Levin N., Khamashta M., King J., Lojacono A. et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann. Rheum. Dis. 2017; 76(3): 476-85.
  38. Rojas-Villarraga A., Torres-Gonzalez J.V., Ruiz-Sternberg Á.M. Safety of hormonal replacement therapy and oral contraceptives in systemic lupus erythematosus: A systematic review and meta-analysis. PLoS One. 2014; 9(8): e104303.
  39. Паневин Т.С., Ананьева Л.П. Патогенетическое обоснование назначения менопаузальной гормонотерапии при системной склеродермии. Научно-практическая ревматология. 2022; 60(4): 538-45. [Panevin T.S., Ananyeva L.P. Pathogenetic rationale for prescribing menopausal hormone therapy for systemic sclerosis. Rheumatology Science and Practice. 2022; 60(4): 538-45. (in Russian)].
  40. Avouac J., Pezet S., Gonzalez V., Baudoin L., Cauvet A., Ruiz B. et al. Estrogens counteract the profibrotic effects of TGF-β and their inhibition exacerbates experimental dermal fibrosis. J. Invest. Dermatol. 2020; 140(3): 593-601.e7. j.jid.2019.07.719.
  41. Lekakis J., Mavrikakis M., Papamichael C., Papazoglou S., Economou O., Scotiniotis I. et al. Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon. Am. Heart J. 1998; 136(5): 905-12.
  42. Haenggi W., Linder H.R., Birkhaeuser M.H., Schneider H. Microscopic findings of the nail-fold capillaries--dependence on menopausal status and hormone replacement therapy. Maturitas. 1995; 22(1): 37-46.
  43. Scorza R., Caronni M., Bazzi S., Nador F., Beretta L., Antonioli R. et al. Post menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann. N. Y. Acad. Sci. 2002; 966: 238-46.
  44. Beretta L., Caronni M., Origgi L., Ponti A., Santaniello A., Scorza R. Hormone replacement therapy may prevent the development of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Scand. J. Rheumatol. 2006; 35(6): 468-71.

Received 01.06.2023

Accepted 24.07.2023

About the Authors

Taras S. Panevin, Ph.D., Endocrinologist, Researcher at the Department of Inflammatory Joint Diseases, V.A. Nasonova Research Institute of Rheumatology, +7(914)207-43-67,, 115522, Russia, Moscow, Kashirskoye Shosse, 34A.
Antonina A. Smetnik, Ph.D., Head of the Department of Gynecological Endocrinology, V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia,, 117997, Russia, Moscow, Ac. Oparina str., 4.

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.